T cell costimulation blockade blunts pressure overload-induced heart failure

Nature Communications

Volumn 8, Issue , 2017, Pages

  Kallikourdis, Marinos ^a,b   Martini, Elisa ^a   Carullo, Pierluigi ^a,c   Sardi, Claudia ^a   Roselli, Giuliana ^a   Greco, Carolina M ^a   Vignali, Debora ^a   Riva, Federica ^d   Ormbostad Berre, Anne Marie ^e   Stølen, Tomas O ^e,f   Fumero, Andrea ^a   Faggian, Giuseppe ^g   Di Pasquale, Elisa ^a,c   Elia, Leonardo ^a,h   Rumio, Cristiano ^d   Catalucci, Daniele ^a,c   Papait, Roberto ^a,c   Condorelli, Gianluigi ^a,b  

^a HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^b HUMANITAS UNIVERSITY   (Italy)

^c Milan Unit   (Italy)

^d UNIVERSITY OF MILAN   (Italy)

^e NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

^f Research Institute of the Norwegian Medical Association   (Norway)

^g UNIVERSITY OF VERONA   (Italy)

^h UNIVERSITY OF BRESCIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; INTERLEUKIN 10; IMMUNOSUPPRESSIVE AGENT;

CARDIOVASCULAR DISEASE; CELLS AND CELL COMPONENTS; DISABILITY; DRUG; HORMONE; MORTALITY; PRESSURE; RODENT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; B LYMPHOCYTE; CARDIAC MUSCLE CELL; CARDITIS; CELL DEATH; CELL STIMULATION; CONTROLLED STUDY; DISEASE SEVERITY; EXPERIMENTAL MODEL; HEART DISEASE; HEART FAILURE; HEART VENTRICLE HYPERTROPHY; HEART VENTRICLE OVERLOAD; HEART VENTRICLE PRESSURE; MACROPHAGE; MALE; MOUSE; NONHUMAN; RHEUMATOID ARTHRITIS; T LYMPHOCYTE; THERAPY EFFECT; ANIMAL; C57BL MOUSE; CARDIOMEGALY; CELL CULTURE; DRUG EFFECT; GENETICS; HUMAN; KNOCKOUT MOUSE; METABOLISM; NEWBORN; PRESSURE;

MUS;

ABATACEPT; ANIMALS; ANIMALS, NEWBORN; CARDIOMEGALY; CELLS, CULTURED; HEART FAILURE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTERLEUKIN-10; MACROPHAGES; MALE; MICE, INBRED C57BL; MICE, KNOCKOUT; PRESSURE; T-LYMPHOCYTES;

EID: 85014595879     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms14680     Document Type: Article

References (67)

1. Zarrinkoub, R., et al. The epidemiology of heart failure, based on data for 2. 1 million inhabitants in Sweden. Eur. J. Heart Fail. 15, 995-1002 (2013).
2. Bulut, D., Creutzenberg, G., Mugge, A. The number of regulatory T cells correlates with hemodynamic improvement in patients with inflammatory dilated cardiomyopathy after immunoadsorption therapy. Scand. J. Immunol. 77, 54-61 (2012).
3. Shioi, T., et al. Increased expression of interleukin-1 beta and monocyte chemotactic and activating factor/monocyte chemoattractant protein-1 in the hypertrophied and failing heart with pressure overload. Circ. Res. 81, 664-671 (1997).
4. Oka, T., et al. Mitochondrial DNA that escapes from autophagy causes inflammation and heart failure. Nature 485, 251-255 (2012).
5. Hofmann, U., Frantz, S. How can we cure a heart 'in flame' A translational view on inflammation in heart failure. Basic Res. Cardiol. 108, 356 (2013).
6. Ancey, C., et al. Secretion of IL-6, IL-11 and LIF by human cardiomyocytes in primary culture. Cytokine 18, 199-205 (2002).
7. Souders, C. A., Borg, T. K., Banerjee, I., Baudino, T. A. Pressure overload induces early morphological changes in the heart. Am. J. Pathol. 181, 1226-1235 (2012).
8. Lai, N. C., et al. Pressure overload-induced cardiac remodeling and dysfunction in the absence of interleukin 6 in mice. Lab. Invest. 92, 1518-1526 (2012).
9. Melendez, G. C., et al. Interleukin 6 mediates myocardial fibrosis, concentric hypertrophy, and diastolic dysfunction in rats. Hypertension 56, 225-231 (2010).
10. Mann, D. L. Inflammatory mediators and the failing heart: past, present, and the foreseeable future. Circ. Res. 91, 988-998 (2002).
11. Yndestad, A., et al. Systemic inflammation in heart failure-the whys and wherefores. Heart Fail. Rev. 11, 83-92 (2006).
12. Loke, P., et al. Alternative activation is an innate response to injury that requires CD4\+ T cells to be sustained during chronic infection. J. Immunol. 179, 3926-3936 (2007).
13. Yu, Q., Horak, K., Larson, D. F. Role of T lymphocytes in hypertensioninduced cardiac extracellular matrix remodeling. Hypertension 48, 98-104 (2006).
14. Moreland, L., Bate, G., Kirkpatrick, P. Abatacept. Nat. Rev. Drug Discov. 5, 185-186 (2006).
15. Rockman, H. A., et al. Segregation of atrial-specific and inducible expression of an atrial natriuretic factor transgene in an in vivo murine model of cardiac hypertrophy. Proc. Natl Acad. Sci. USA 88, 8277-8281 (1991).
16. Kuang, S. Q., et al. Aortic remodeling after transverse aortic constriction in mice is attenuated with AT1 receptor blockade. Arterioscler. Thromb. Vasc. Biol. 33, 2172-2179 (2013).
17. Xia, Y., et al. Characterization of the inflammatory and fibrotic response in a mouse model of cardiac pressure overload. Histochem. Cell Biol. 131, 471-481 (2009).
18. Mantovani, A., et al. The chemokine system in diverse forms of macrophage activation and polarization. Trends Immunol. 25, 677-686 (2004).
19. Wynn, T. A. Fibrotic disease and the T(H)1/T(H)2 paradigm. Nat. Rev. Immunol. 4, 583-594 (2004).
20. Perrino, C., et al. Intermittent pressure overload triggers hypertrophyindependent cardiac dysfunction and vascular rarefaction. J. Clin. Invest. 116, 1547-1560 (2006).
21. Kemi, O. J., et al. Activation or inactivation of cardiac Akt/mTOR signaling diverges physiological from pathological hypertrophy. J. Cell Physiol. 214, 316-321 (2008).
22. Condorelli, G., et al. Akt induces enhanced myocardial contractility and cell size in vivo in transgenic mice. Proc. Natl Acad. Sci. USA 99, 12333-12338 (2002).
23. Roncarati, R., et al. Doubly heterozygous LMNA and TTN mutations revealed by exome sequencing in a severe form of dilated cardiomyopathy. Eur. J. Hum. Genet. 21, 1105-1111 (2013).
24. Ross, J., Braunwald, E. Aortic stenosis. Circulation 38, 61-67 (1968).
25. Wing, K., Sakaguchi, S. Regulatory T cells exert checks and balances on self tolerance and autoimmunity. Nat. Immunol. 11, 7-13 (2010).
26. Condorelli, G., et al. Increased cardiomyocyte apoptosis and changes in proapoptotic and antiapoptotic genes bax and bcl-2 during left ventricular adaptations to chronic pressure overload in the rat. Circulation 99, 3071-3078 (1999).
27. Kong, P., Christia, P., Frangogiannis, N. G. The pathogenesis of cardiac fibrosis. Cell Mol. Life Sci. 71, 549-574 (2014).
28. Platt, A. M., et al. Abatacept limits breach of self-tolerance in a murine model of arthritis via effects on the generation of T follicular helper cells. J. Immunol. 185, 1558-1567 (2010).
29. Dhirapong, A., et al. Therapeutic effect of cytotoxic T lymphocyte antigen 4/immunoglobulin on a murine model of primary biliary cirrhosis. Hepatology 57, 708-715 (2013).
30. Linsley, P. S., et al. CTLA-4 is a second receptor for the B cell activation antigen B7. J. Exp. Med. 174, 561-569 (1991).
31. Bluestone, J. A. Is CTLA-4 a master switch for peripheral T cell tolerance J. Immunol. 158, 1989-1993 (1997).
32. Krummey, S. M., Ford, M. L. Braking bad: novel mechanisms of ctla-4 inhibition of T cell responses. Am. J. Transplant. 14, 2685-2690 (2014).
33. Wenink, M. H., et al. Abatacept modulates proinflammatory macrophage responses upon cytokine-activated T cell and Toll-like receptor ligand stimulation. Ann. Rheum. Dis. 71, 80-83 (2012).
34. Mihara, M., et al. CTLA4Ig inhibits T cell-dependent B-cell maturation in murine systemic lupus erythematosus. J. Clin. Invest. 106, 91-101 (2000).
35. Epelman, S., et al. Embryonic and adult-derived resident cardiac macrophages are maintained through distinct mechanisms at steady state and during inflammation. Immunity 40, 91-104 (2014).
36. Utans, U., Arceci, R. J., Yamashita, Y., Russell, M. E. Cloning and characterization of allograft inflammatory factor-1: a novel macrophage factor identified in rat cardiac allografts with chronic rejection. J. Clin. Invest. 95, 2954-2962 (1995).
37. Tian, Y., Kelemen, S. E., Autieri, M. V. Inhibition of AIF-1 expression by constitutive siRNA expression reduces macrophage migration, proliferation, and signal transduction initiated by atherogenic stimuli. Am. J. Physiol. Cell Physiol. 290, C1083-C1091 (2006).
38. Heidt, T., et al. Differential contribution of monocytes to heart macrophages in steady-state and after myocardial infarction. Circ. Res. 115, 284-295 (2014).
39. Ponsoye, M., et al. Treatment with abatacept prevents experimental dermal fibrosis and induces regression of established inflammation-driven fibrosis. Ann. Rheum. Dis. 75, 2142-2149 (2016).
40. Sage, P. T., Paterson, A. M., Lovitch, S. B., Sharpe, A. H. The coinhibitory receptor CTLA-4 controls B cell responses by modulating T follicular helper, T follicular regulatory, and T regulatory cells. Immunity 41, 1026-1039 (2014).
41. Verma, S. K., et al. Interleukin-10 treatment attenuates pressure overload-induced hypertrophic remodeling and improves heart function via signal transducers and activators of transcription 3-dependent inhibition of nuclear factor-kappaB. Circulation 126, 418-429 (2012).
42. Serra, A. J., et al. Exercise training inhibits inflammatory cytokines and more than prevents myocardial dysfunction in rats with sustained beta-adrenergic hyperactivity. J. Physiol. 588, 2431-2442 (2010).
43. Niedermeier, M., et al. CD4\+ T cells control the differentiation of Gr1\+ monocytes into fibrocytes. Proc. Natl Acad. Sci. USA 106, 17892-17897 (2009).
44. Peng, H., et al. Angiotensin II-induced dilated cardiomyopathy in Balb/c but not C57BL/6 J mice. Exp. Physiol. 96, 756-764 (2011).
45. Laroumanie, F., et al. CD4\+ T cells promote the transition from hypertrophy to heart failure during chronic pressure overload. Circulation 129, 2111-2124 (2014).
46. Nevers, T., et al. Left ventricular T cell recruitment contributes to the pathogenesis of heart failure. Circ. Heart Fail. 8, 776-787 (2015).
47. Tang, T. T., et al. Defective circulating CD4CD25\+Foxp3\+CD127(low) regulatory T cells in patients with chronic heart failure. Cell Physiol. Biochem. 25, 451-458 (2010).
48. Garetto, S., et al. Peak inflammation in atherosclerosis, primary biliary cirrhosis and autoimmune arthritis is counter-intuitively associated with regulatory T cell enrichment. Immunobiology 220, 1025-1029 (2015).
49. Kvakan, H., et al. Regulatory T cells ameliorate angiotensin II-induced cardiac damage. Circulation 119, 2904-2912 (2009).
50. Kanellakis, P., Dinh, T. N., Agrotis, A., Bobik, A. CD4\+CD25\+Foxp3\+ regulatory T cells suppress cardiac fibrosis in the hypertensive heart. J. Hypertens. 29, 1820-1828 (2011).
51. Tang, T. T., et al. Regulatory T cells ameliorate cardiac remodeling after myocardial infarction. Basic Res. Cardiol. 107, 232 (2012).
52. Weirather, J., et al. Foxp3\+CD4\+ T cells improve healing after myocardial infarction by modulating monocyte/macrophage differentiation. Circ. Res. 115, 55-67 (2014).
53. Suntharalingam, G., et al. Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. N. Engl. J. Med. 355, 1018-1028 (2006).
54. Kumar, P., Francis, G. S., Tang, W. H. Phosphodiesterase 5 inhibition in heart failure: mechanisms and clinical implications. Nat. Rev. Cardiol. 6, 349-355 (2009).
55. Hu, Y. F., Chen, Y. J., Lin, Y. J., Chen, S. A. Inflammation and the pathogenesis of atrial fibrillation. Nat. Rev. Cardiol. 12, 230-243 (2015).
56. Linsley, P. S., Nadler, S. G. The clinical utility of inhibiting CD28-mediated costimulation. Immunol. Rev. 229, 307-321 (2009).
57. M., Nadler, S. G. Advances in CTLA-4-Ig-mediated modulation of inflammatory cell and immune response activation in rheumatoid arthritis. Autoimmun. Rev. 12, 758-767.
58. Mitamura, M., et al. T cells are involved in the development of arthritis induced by anti-type II collagen antibody. Int. Immunopharmacol. 7, 1360-1368 (2007).
59. Davis, P. M., Nadler, S. G., Stetsko, D. K., Suchard, S. J. Abatacept modulates human dendritic cell-stimulated T-cell proliferation and effector function independent of IDO induction. Clin. Immunol. 126, 38-47 (2008).
60. Carman, J. A., et al. Abatacept does not induce direct gene expression changes in antigen-presenting cells. J. Clin. Immunol. 29, 479-489 (2009).
61. Cutolo, M., et al. CTLA4-Ig interacts with cultured synovial macrophages from rheumatoid arthritis patients and downregulates cytokine production. Arthritis Res. Ther. 11, R176 (2009).
62. Ko, H. J., et al. CTLA4-Ig modifies dendritic cells from mice with collagen-induced arthritis to increase the CD4\+CD25\+Foxp3\+ regulatory T cell population. J. Autoimmun. 34, 111-120 (2010).
63. Saxena, A., et al. Interleukin-10 paradox: A potent immunoregulatory cytokine that has been difficult to harness for immunotherapy. Cytokine 74, 27-34 (2015).
64. Marschallinger, J., et al. Structural and functional rejuvenation of the aged brain by an approved anti-asthmatic drug. Nat. Commun. 6, 8466 (2015).
65. Liu, Z., et al. IFN-alpha confers resistance of systemic lupus erythematosus nephritis to therapy in NZB/W F1 mice. J. Immunol. 187, 1506-1513 (2011).
66. Ma, K., et al. CTLA4-IgG ameliorates homocysteine-accelerated atherosclerosis by inhibiting T-cell overactivation in apoE(-/-) mice. Cardiovasc. Res. 97, 349-359 (2013).
67. Stolen, T. O., et al. Interval training normalizes cardiomyocyte function, diastolic Ca2\+ control, and SR Ca2\+ release synchronicity in a mouse model of diabetic cardiomyopathy. Circ. Res. 105, 527-536 (2009).